JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two mid-stage studies. Truist says that Abbvie’s “pain” is ...

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...

Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of ...

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Shares of AbbVie have dropped sharply ...

AbbVie investors that bought the anxiety over ... I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned ...

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool has a disclosure policy.

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

Emraclidine was part of AbbVie's acquisition of Cerevel last year, which also included Tavapadon, which reported positive Phase 3 data. Bristol's Cobenfy is now poised to dominate the ...

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent $9 billion ...

Neuroscience is a key area of focus for AbbVie. In addition to emraclidine, through the Cerevel acquisition AbbVie gained a neuroscience pipeline of multiple clinical-stage and preclinical ...